Anti-hIL-6R IgA2 antibody | Tocilizumab biosimilar isotypes

Product	Unit size	Cat. code	Docs.	Qty.	Price
Anti-hIL6R-To-hIgA2 Human IL-6R (Tocilizumab) antibody - Human IgA2 Anti-hIL6R-To-hIgA2 Human IL-6R (Tocilizumab) antibody - Human IgA2 Add to favorite Add to favorite	Show product	100 µg 3 x 100 µg	hil6rto-mab7 hil6rto-mab7-03		+- +-	$109 $298

Human IgA2 monoclonal antibody (mAb) against human IL-6R

InvivoGen provides Anti-hIL-6R-hIgA2, a monoclonal antibody (mAb) featuring:

the variable region of tocilizumab targeting the human interleukin 6 receptor (IL-6R)
a IgA2 constant region mediating low effector functions

InvivoGen's Anti-hIL6R-hIgA2 was generated by recombinant DNA technology, produced in Chinese hamster ovary (CHO) cells, and purified by affinity chromatography. Each lot is functionally tested by flow cytometry and cellular assays (see figures).

Key features of the Anti-hIL6R-hIgA2

Clinically-relevant variable region targeting human IL-6R (Tocilizumab).
Human Ig1A constant region for low effector functions
Inhibition of IL-6-dependent signaling by Anti-hIL6R-To mAbs has been validated in HEK-Blue™ IL-6 cellular assays.
The absence of bacterial contamination has been confirmed.

IL-6R background

Tocilizumab (TCZ) is a recombinant, humanized monoclonal antibody (mAb) directed against both soluble and membrane-bound human IL-6R. TCZ exhibits anti-inflammatory activity by inhibiting the binding of the pro-inflammatory cytokine, IL-6 to its receptor [1]. IL-6 exerts its biological effects through IL-6R, and the transmembrane protein gp130. Despite only a few cells expressing IL-6R on their surface, many cells respond to IL-6 due to the existence of soluble IL-6R [2]. TCZ can block both modes of signaling [1]. TCZ has been approved for the treatment of inflammatory diseases and conditions such as rheumatoid arthritis (RA) and cytokine release syndrome (CRS), a side effect of CAR-T therapy. Furthermore, it is under investigation for the treatment of the late-stage hyperinflammation observed in severe COVID‑19 patients [3].

COVID-19 related research

Severe COVID-19 patients have been shown to exhibit high levels of pro-inflammatory cytokines, such as IL-6, which can ultimately initiate life-threatening hyper-inflammation and a “cytokine storm” in the lungs and other organs. Tocilizumab is being explored as a potential therapeutic in the treatment of these patients.

Read our reviews on COVID-19 and learn more about SARS-CoV-2 infection cycle, immune responses, and potential therapeutics.

References

1. Sheppard, M. et al. 2017. Tocilizumab (Actemra). Hum Vaccin Immunother 13, 1972- 1988.
2. Rose-John, S. 2012. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci 8, 1237-1247.
3. Zhang, S. et al. 2020. Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia. Clin Drug Investig.

Figures

Inhibition of IL-6R signaling by Anti-hIL6R-To-hIgA2

Back to the top

Specifications

Specificity: Human Interleukin-6 receptor (hIL-6R)

Clonality: Monoclonal antibodies

Clone: Tocilizumab (Anti-hIL-6R-hIgG1, kappa)

Control: Human IgA2

Source: CHO cells

Formulation: 0.2 μm filtered solution in a sodium phosphate buffer with glycine, saccharose, and stabilizing agents.

Tested application: Functional assay

Purification: Purified by affinity chromatography with peptide M

Quality control:

The complete sequence of each antibody construct has been verified.
Each antibody lot has been functionally validated using HEK-Blue™ IL-6 cellular assays
The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cellular assays.